Generalised access to early diagnosis and treatment and targeted mass drug administration on Plasmodium falciparum malaria in Eastern Myanmar

• Drug & regimen: 3 consecutive rounds were administered 1 month apart of dihydroartemisinin–piperaquine (7 mg/kg -55 mg/kg orally) + single-dose primaquine (0.25mg/kg) through delivery at the malaria posts
• Concomitant interventions: Increased access to early diagnosis and treatment through community-based malaria posts, community engagement
• Exclusion criteria: Children younger than 6 months, individuals with a known allergy to the antimalarial drugs, women in the first trimester of pregnancy. Women in the second and third trimester of pregnancy, as well as breastfeeding mothers, were eligible for DP treatment but were excluded from the single dose of primaquine.
• Outcome measures: 
  • Change in village incidence measured from RDT confirmed cases at the community health post (malaria post)
  • Change in prevalence, measured using highly sensitive qPCR approach (before and after MDA)

Type: Interventional
Allocation: Non- Randomized
Intervention model: Single-group
Masking: Non (open label)
Primary purpose: Prevention

Drug-based Strategies

Jan 2014 — Dec 2017

Myanmar

Malaria Elimination Task Force

Mass Drug Administration (MDA)